Stephen Dubois is optimistic about the prospects of Genomic Health, Inc. (NASDAQ:GHDX) and has increased his fund’s holding of the stock. As reported in a recent filing with the Securities and Exchange Commission, Dubois’ fund, Camber Capital Management, now holds 1.72 million shares, up from the 750,000 shares reported in its latest 13F filing. As a result, Camber and Dubois now have control over 5.52% of the Genomic Health’s common stock.
Genomic Health, Inc. (NASDAQ:GHDX) has also attracted the attention of Ken Griffin and Israel Englander. During the first quarter of this year, Griffin’s Citadel Investment Group increased its holding of the stock by 28% to approximately 206,400 shares. Englander has also boosted his fund’s stake by 35%, taking it to 370,000 shares. Julian Baker and Felix Baker are also keeping tabs, with their fund, Baker Bros. Advisors, reporting ownership of 13.6 million shares in its latest 13F filing.
A provider of genomic-based clinical laboratory services, Genomic Health, Inc. (NASDAQ:GHDX) has seen its stock depreciate by 4% so far this year to a current price of $28.07 per share, which gives the company a market cap of $876 million. For the three months ending March 31, 2014, Genomic Health has reported revenues of $67 million, a year-over-year increase of 6.2% and a loss per share of $0.24. For the second quarter analysts estimate a loss of $0.26 per share and $69 million in revenues.
Dubois is also betting on Sequenom Inc. (NASDAQ:SQNM), having recently increased his fund’s stake to 6.30 million shares or 5.41% of the total number of shares outstanding. Another company Dubois sees value in is Cardica, Inc. (NASDAQ:CRDC). Camber Capital has reported a new position at the end of April, amassing 8.37 million shares, which account for approximately 10% of the common stock. The biggest equity position in Camber’s portfolio continues to be Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), although Dubois has decreased it by 18% during the first quarter of 2014 to 1.65 million shares.